Fluor Corp. (Irving, Tex.) announced that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California.
“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”
Bayer’s new biomanufacturing center in Berkeley has been completed (Source: Fluor)
The new state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs.
Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.
Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.